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ABSTRACT
PTEN loss is prognostic for patient relapse post-radiotherapy in prostate 
cancer (CaP). Infiltration of tumor-associated macrophages (TAMs) is associated 
with reduced disease-free survival following radical prostatectomy. However, 
the association between PTEN loss, TAM infiltration and radiotherapy response of 
CaP cells remains to be evaluated. Immunohistochemical and molecular analysis 
of surgically-resected Gleason 7 tumors confirmed that PTEN loss correlated with 
increased CXCL8 expression and macrophage infiltration. However PTEN status had no 
discernable correlation with expression of other inflammatory markers by CaP cells, 
including TNF-α. In vitro, exposure to conditioned media harvested from irradiated 
PTEN null CaP cells induced chemotaxis of macrophage-like THP-1 cells, a response 
partially attenuated by CXCL8 inhibition. Co-culture with THP-1 cells resulted in a 
modest reduction in the radio-sensitivity of DU145 cells. Cytokine profiling revealed 
constitutive secretion of TNF-α from CaP cells irrespective of PTEN status and  
IR-induced TNF-α secretion from THP-1 cells. THP-1-derived TNF-α increased NFκB 
pro-survival activity and elevated expression of anti-apoptotic proteins including 
cellular inhibitor of apoptosis protein-1 (cIAP-1) in CaP cells, which could be 
attenuated by pre-treatment with a TNF-α neutralizing antibody. Treatment with a 
novel IAP antagonist, AT-IAP, decreased basal and TNF-α-induced cIAP-1 expression 
in CaP cells, switched TNF-α signaling from pro-survival to pro-apoptotic and 
increased radiation sensitivity of CaP cells in co-culture with THP-1 cells. We conclude 
that targeting cIAP-1 can overcome apoptosis resistance of CaP cells and is an ideal 
approach to exploit high TNF-α signals within the TAM-rich microenvironment of 
PTEN-deficient CaP cells to enhance response to radiotherapy.
INTRODUCTION
Radiotherapy (RT) constitutes a major treatment 
modality used in patients presenting with localized 
prostate cancer (CaP) [1]. Despite RT and surgery 
being curative in up to 50% of patients, approximately 
one third of men will exhibit biochemical recurrence 
and disease progression towards fatal castrate-resistant 
prostate cancer (CRPC) [2, 3]. Loss of the 
haplo-insufficient tumor suppressor PTEN has recently 
been identified as a prognostic factor for patient relapse 
following RT [4]. Furthermore, we have previously 
identified the chemokine CXCL8 as a mediator of 
PTEN-deficient tumorigenesis [5].
The revised “Hallmarks of Cancer” emphasizes 
the importance of the tumor microenvironment in 
tumorigenesis [6]. An increasing number of reports 
also highlight the impact of microenvironment-derived 
inflammatory cytokine signaling or stromal-derived 
pro-angiogenic signals in driving radioresistance 
[7, 8]. Surprisingly, knowledge of microenvironment-
mediated radioresistance in CaP is poorly characterized 
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but given the strong association of inflammation with the 
disease, there is a high potential that the immune cell 
infiltrate may modulate the overall tumor response to RT 
in early-stage disease. Tumor-associated macrophages 
(TAM) have been identified as a significant component of 
the inflammatory cell infiltrate in CaP and may influence 
disease progression through their ability to release soluble 
signaling factors within the tumor boundaries [9, 10]. TAM 
infiltration has previously been correlated with disease 
free survival (DFS) following radical prostatectomy (RP) 
(11–13). However, no such studies have been reported 
regarding RT response.
TNF-α is a cytokine primarily produced by 
macrophages and activates the extrinsic apoptosis pathway 
following its binding to cell surface death receptors on 
tumor cells [11, 12]. CaP cells are notoriously resistant to 
the action of TNF-α, and rather than promoting apoptosis, 
TNF-α instead preferentially promotes the activation 
of NFκB-dependent pro-survival signaling [13, 14]. 
This switch from death-promoting to survival signaling 
is regulated by the expression and function of the cellular 
inhibitor of apoptosis protein-1 and -2 (cIAP-1 and cIAP-2) 
(18). Overexpression of cIAP-1 may therefore underpin 
resistance of CaP cells to TNF-α. In addition, therapeutic 
targeting of cIAP-1 may serve as a potent strategy to 
sensitize CaP cells to TNF-α mediated cell death.
Under normal conditions, cIAP-1 expression is 
tightly regulated by the action of mitochondrial protein 
Smac. Loss of mitochondrial membrane permeability 
results in release of Smac into the cytosol where it can 
induce proteosomal degradation of cIAP-1 and cIAP-2, 
whilst directly inhibiting XIAP [15, 16]. Dysfunctional 
Smac-mediated regulation of apoptosis is a common feature 
in malignant disease and has resulted in the development 
of a novel class of drugs known as Smac-mimetics 
[17, 18]. AT-IAP is a dual cIAP-1 and XIAP antagonist 
which has demonstrated pre-clinical efficacy, in 
combination with the histone deacetylase inhibitor 
vorinostat, in models of mesothelioma [19].
This study aimed to determine the impact of TAM 
infiltration, and specifically the effects of treatment-induced 
TNFα signaling in modulating RT response of CaP 
cells. We show that administration of the c-IAP/x-IAP 
antagonist, AT-IAP, directs a pro-apoptotic response to 
TNF-α signaling, increasing the sensitivity of prostate 
cancer cells to RT. Furthermore, this raises the potential to 
utilize radiotherapy beyond the localized stage of disease.
RESULTS
Depleted PTEN expression in patient samples 
correlates with increased CXCL8 expression
We have previously proposed that augmentation of 
CXCL8 signaling is a crucial mediator of PTEN-depleted 
tumorigenesis in CaP [5]. To verify our prior in vitro 
cell-line-derived data, we conducted a molecular analysis 
on 28 surgically-resected Gleason 7 tumors to establish 
the correlation of PTEN status against CXCL8 gene 
expression. Molecular profiling by high throughput 
gene expression discriminated these samples into two 
cohorts, stratified on either high or low PTEN expression. 
Validation experiments confirmed separation of these 
distinct PTEN populations using RT-PCR analysis of 
mRNA expression (p < 0.001; Figure 1A). Cytokine 
profiling of these samples confirmed that low PTEN 
mRNA expression was correlative with increased CXCL8 
mRNA (Spearman correlation: −0.5088; p = 0.0261) 
(Figure 1B). Conversely, subsequent profiling of these 
macro-dissected tumor samples confirmed that PTEN 
status did not correlate with significant changes in intrinsic 
expression of other cytokines including IL-6 (Spearman 
correlation: −0.1091; p = 0.6378) (Figure 1C). Other 
cytokines analyzed included CXCL1, CXCL2 and CXCL5 
(data not shown).
CXCL8 induces chemotaxis of radioresistance-
promoting THP1’s in a PTEN-deficient setting
CXCL8 was initially characterized as a potent 
chemoattractant for leukocyte-derived immune cells [22]. 
Given the up-regulation of CXCL8 expression detected 
in PTEN-deficient tumors, further IHC analysis was 
performed to characterize the levels of CD68-positive 
macrophages detected within prostate patient samples 
(Figure 2A). Moderate to dense infiltration of 
CD68-positive macrophages was correlated with loss 
of PTEN protein expression across 70 analyzable cases 
(p < 0.05). Lower levels of macrophage infiltration were 
detected within PTEN-positive tumors (Figure 2B). 
In vitro assays confirmed the function of CXCL8 in 
potentiating chemotactic migration of THP-1 cells, used 
in this context as a representative macrophage-like cell 
[243 ± 66% above baseline migration towards 
serum-free medium; (Figure 2C)]. Furthermore, our assays 
demonstrated that the conditioned media (CM) harvested 
from irradiated PTEN-deficient Sh11.02 cells was capable 
of inducing THP-1 chemotaxis, and that this response 
could be partially inhibited following pre-treatment with 
a CXCL8 neutralizing antibody; however, this effect was 
not observed in PTEN-expressing NT01 cells (Figure 2D). 
Irradiating CaP cells can induce release of a multitude of 
cytokines (data not shown) and therefore total inhibition 
of cell migration may not be possible without considering 
this extensive signaling network.
To establish how macrophage infiltration may affect 
therapeutic response, colony formation assays were used 
to characterize radiation sensitivity of PTEN-modulated 
DU145 cells, cultured in the presence or absence of THP-1 
cells. Co-culture with THP-1 cells increased the resistance 
of both PTEN-positive NT01 and PTEN-deficient Sh11.02 
cells to ionizing radiation (IR), with calculated dose 
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Figure 1: Comparative analysis of PTEN-status and cytokine expression in prostate cancer patient samples. 
(A) Scatter plot showing validation of PTEN-status profiling in prostate cancer patient samples. The data presented confirms loss of PTEN 
mRNA expression following cohort separation by RT-PCR. (B) Scatter plot showing CXCL8 gene expression in prostate cancer patient 
samples separated by PTEN mRNA status. (C) Scatter plot showing IL-6 gene expression in prostate cancer patient samples separated by 
PTEN mRNA status. Statistically significant differences were determined using the Spearman correlation protocol (*p < 0.05; **p < 0.01; 
***p < 0.001).
Oncotarget4www.impactjournals.com/oncotarget
enhancement factors (DEF) of 0.89 and 0.87, respectively. 
The equivalent degree of sensitization observed suggests 
that the mechanism of macrophage-afforded resistance 
was independent of the intrinsic PTEN status of the 
CaP cells (Figure 2E and 2F). These experiments were 
repeated in the PTEN-null PC3 cell line and although 
showing a trend towards monocyte-driven radioresistance 
at the higher dose points, no significant difference in 
radiosensitivity was observed (Supplementary Figure 1A). 
This was also the case when PTEN expression was 
reconstituted under the control of a tetracycline-inducible 
promoter (Supplementary Figure 1B).
IR induces secretion of TNF-α from THP-1 cells 
but not from CaP cells
Alongside CXCL8, the cytokine TNF-α has recently 
been implicated with reduced overall survival and time to 
castration resistance in CaP patients [23]. Therefore the 
linkage of PTEN status to TNF-α expression in malignant 
prostate cells was also determined. Analysis of DU145 
NT01 and Sh11.02 cells indicated that loss of PTEN 
had no effect on TNF-α secretion or mRNA levels in 
these isogenic lines (Supplementary Figure 2A and 2B). 
Furthermore, analysis of patient samples confirmed no 
Figure 2: CXCL8 induces chemotaxis of radioresistance-promoting macrophages in a PTEN-deficient setting. 
(A) Immunohistochemical staining of PTEN and CD68 in a prostate tissue microarray (n = 70). Presented images representative of results 
across all cases. (B) Bar graph demonstrating the correlation between PTEN status and CD68. Statistical analysis was performed using a 
Chi-squared test; p = 0.011. (C) Bar graph showing the effect of 3 nM CXCL8 in modulating cell migration of THP-1 cells. (D) Bar graph 
demonstrating the effect of conditioned serum-free media from irradiated PTEN-expressing DU145 NT01 and PTEN-depleted DU145 
Sh11.02 cells on THP-1 cell migration. The addition of a CXCL8 neutralizing antibody represses IR-induced cell migration. Clonogenic 
survival curves showing the effect of THP-1 co-culture on the radiation response of (E) NT01 and (F) Sh11.02 cells. Data shown is the 
mean plus or minus standard error of the mean value, calculated from a minimum of three independent experiments. Statistically significant 
differences were determined by performing a two-tailed Students t-test for migration experiments or two-way ANOVA for clonogenic 
assays (*p < 0.05; **p < 0.01; ***p < 0.001).
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correlation between PTEN mRNA levels and TNF-α gene 
expression (Spearman correlation: −0.1175; p = 0.6318) 
(Figure 3A). Since we observed no intrinsic correlation 
of PTEN with TNF-α expression, experimental results 
shown are derived from analysis of the PTEN-deficient 
Sh11.02 cell line while corresponding results derived from 
PTEN-positive NT01 cells presented in Supplementary 
Figures 2, 3 and 4. 
The effect of radiation exposure upon TNF-α 
secretion in CaP cells was also determined. Treatment 
of PTEN-deficient Sh11.02 cells with 3 Gy IR did not 
augment TNF-α secretion levels compared to time-matched 
control samples, ranging from between 20–80 pg/ml/106 
cells across a 24 h time course (Figure 3B). Ionizing 
radiation also had no effect on TNF-α mRNA or protein 
expression (Supplementary Figure 2) or on expression 
of tumor necrosis factor receptor-1 (TNFR-1) in these 
cells (Figure 3C). Consistent with the secretion of 
TNF-α and capacity of DU145 Sh11.02 cells and DU145 
NT01 cells to respond in an autocrine manner, addition 
of 10 ng/ml recombinant-human TNF-α (rh-TNF-α) 
had a minimal impact on radiation sensitivity as determined 
in clonogenic assays (Supplementary Figure 5). 
Macrophages are a rich source of pro-inflammatory 
TNF-α. Justified by the enrichment of CD68-positive 
macrophages detected by IHC in PTEN-deficient prostate 
tumors, we assessed how exposure to IR modulated 
TNF-α secretion from THP-1 cells. Treatment with 3 
Gy IR promoted a rapid increase in the level of TNF-α 
secretion observed, with a 21.09 ± 5.5 fold increase 
evident within 30 min of exposure (Figure 3D). 
In addition, we also characterized whether the secretion of 
CXCL8 from PTEN-deficient tumor cells may affect the 
level of macrophage-derived TNF-α secretion. Treatment 
with recombinant human-CXCL8 (rh-CXCL8; 3 nM) 
was shown to induce the secretion of TNF-α from 
THP-1’s, though secretion levels were shown to peak as a 
consequence of prolonged stimulation (Figure 3E). Thus 
the release of CXCL8 from the PTEN-deficient tumor cells 
may also potentiate the IR-induced, macrophage-derived 
elevation of TNF-α signaling within the microenvironment 
of PTEN-deficient tumors.
IR-induced TNF-α from THP-1’s promotes NFκB-
mediated pro-survival signaling in CaP cells
Experiments were conducted to evaluate how 
addition of THP-1 cells affected the degree of NFκB 
activation observed in DU145 Sh11.02 cells, in the 
absence and presence of radiation. Co-culture with 
THP-1 cells alone increased the level of NFκB activity 
within Sh11.02 cells by 60.1 ± 7.8% (p < 0.01). However, 
irradiation of the DU145 Sh11.02/THP-1 co-culture model 
promoted a 233.6 ± 44.3% increase in NFκB activity, as 
detected by luciferase reporter assays (p < 0.01). The 
increase in NFκB-driven luciferase activity was attenuated 
but not abrogated in the presence of a TNF-α neutralizing 
antibody (p < 0.05; Figure 4A). Similar results were 
observed in the PTEN-expressing DU145 NT01 cell line 
(Supplementary Figure 3B). 
The effect of NFκB activation on the expression 
of downstream pro-survival effectors was evaluated by 
immunoblotting. Of the proteins analyzed, only basal 
expression of Bcl-2 was different between unstimulated 
PTEN-expressing NT01 and PTEN-deficient Sh11.02 cells 
(Figure 4B). To model the effects of radiation-induced 
TNF-α secretion from THP-1 cells, we stimulated 
Sh11.02 cells with a 10 ng/ml bolus of rhTNF-α over 
a 24 h time course. Analysis of Sh11.02 protein lysates 
identified that rhTNF-α increased the expression of several 
anti-apoptotic proteins including c-FLIP, cIAP-1, cIAP-2 
and Bcl-2, whilst having no effect on levels of caspase 8 
(Figure 4C). Furthermore, exposure of our Sh11.02/THP-1 
co-culture system to 3 Gy IR further elevated the 
expression of c-FLIP (L) and noticeably increased cIAP-1 
levels after 4 h (Figure 4D). Interestingly, this increase in 
cIAP-1 expression could be prevented by pre-treating with 
a TNF-α neutralizing antibody.
Given the coupling of TNF-α signaling to 
pro-survival protein expression, we conducted colony 
count assays to determine whether repression of 
IR-induced, macrophage-derived TNF-α signaling 
could influence cell survival. Administration of a 
neutralizing antibody to TNF-α failed to decrease cell 
survival at clinically-relevant doses of IR in either 
the DU145 NT01 or Sh11.02 cells (Supplementary 
Figure 5B and 5D respectively). However, a 
degree of enhancement was seen to high dose IR 
at levels which are currently under investigation in 
hypo-fractionation protocols. 
AT-IAP induces CaP cell apoptosis through 
inhibition of cIAP-1
Determining that TNF-α signaling preferentially 
induced a NFκB pro-survival phenotype raised the 
potential of targeting upregulated transcriptional targets 
of this pathway. One of these anti-apoptotic regulators 
was cIAP1; a protein which is normally under tight 
regulation via the ability of mitochondrial Smac to 
induce proteosomal degradation. AT-IAP is a novel dual 
antagonist of cIAP and XIAP and leads to degradation 
of cIAP-1. Treatment of DU145 Sh11.02 cells with 0.1, 
1 or 10 µM AT-IAP for 4 h significantly reduced cIAP-1 
protein expression (Figure 5A). Addition of TNF-α 
or monotherapy with AT-IAP had no effect on the 
cell viability of PTEN-deficient DU145 Sh11.02 cells 
as determined by MTT assay. However, concurrent 
administration of TNF-α and AT-IAP reduced cell 
viability by 44.2 ± 6.5% (p < 0.05; Figure 5B). Annexin 
V-detection by flow cytometry (72 h) and quantitative 
caspase 3/7 assays (24 h) confirmed that the combination 
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of 10 ng/ml rhTNF-α and 1 µM AT-IAP enhanced the 
promotion of apoptosis relative to control. Combination 
therapy with rhTNF-α and AT-IAP increased the Annexin-
V-positive cell population by 17.8 ± 4.02% over controls, 
and induced a 4.7 ± 0.26 fold increase in caspase 3/7 
activity (p < 0.01; Figure 5C and 5D). Consistent with 
their inability to significantly impact cell viability in MTT 
assays, administration of rhTNF-α or AT-IAP alone did 
not significantly increase apoptosis induction. Similar 
results were obtained for all these experiments in PTEN-
expressing DU145 NT01 cells (Supplementary Figure 4).
AT-IAP increases radiosensitivity of CaP cells 
following THP-1 co-culture via modulation of 
apoptosis
The ability of AT-IAP to down-regulate cIAP-1 
expression in DU145 Sh11.02 cells, cultured in the 
presence of macrophages and exposed to IR, was 
assessed by immunoblotting assays. Treatment with 1 µM 
AT-IAP for 4 h was sufficient to reverse 3 Gy IR and 
microenvironment-driven, THP-1 mediated increases in 
cIAP-1 expression (Figure 6A). The addition of AT-IAP 
and the potent down-regulation of cIAP-1 was sufficient 
in elevating caspase 3/7 activity, in the presence of the 
radiation-induced TNF-α release within the co-culture 
system (Figure 6B). Furthermore, addition of AT-IAP 
increased the radiation sensitivity of DU145 Sh11.02 cells 
in the presence of THP-1 cells, resulting in a calculated 
DEF of 1.53 (p < 0.001; Figure 6C). Interestingly, 
this effect was only partially knocked back following 
addition of a TNF-α neutralizing antibody (p < 0.001), 
suggesting that other monocyte-derived secreted factors 
may by influencing CaP cell radiosensitivity. AT-IAP also 
enhanced the radiation sensitivity of PTEN-expressing 
DU145 NT01 cells (Supplementary Figure 4E).
Figure 3: Impact of ionizing radiation and PTEN-status on TNF-α signaling in prostate cancer and THP-1 cell lines. 
(A) Scatter plot illustrating TNF-α gene expression in prostate cancer patient samples classified by PTEN mRNA levels. (B) Bar graph 
showing TNF-α secretion from PTEN-depleted Sh11.02 cells following treatment with a single 3 Gy dose of IR. (C) Immunoblot 
demonstrating the impact of 3 Gy IR on TNFR-1 expression in Sh11.02 cells. (D) Bar graph showing TNF-α secretion levels from THP-
1 cells following treatment with 3 Gy IR. (E) Bar graph showing TNF-α secretion levels from THP-1 cells following treatment with 3 
nM CXCL8. Data shown is the mean plus or minus standard error of the mean value, calculated from a minimum of three independent 
experiments. Statistically significant differences were determined by performing a two-tailed Students t-test (*p < 0.05; **p < 0.01; 
***p < 0.001).
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DISCUSSION
Loss of the tumor suppressor PTEN is prevalent 
in men presenting with organ-confined prostate cancer 
and has prognostic value towards predicting poor 
response to radiotherapy [4]. We have previously shown 
that impairment of PTEN function correlates with an 
elevated expression of the CXC-chemokine CXCL8 in 
in vitro models and its orthologous chemokine KC in 
the prostate epithelium of PTEN+/− mice [5]. In addition 
to the definition of several autocrine functions, CXCL8 
has the potential to register profound effects on the tumor 
microenvironment, predominantly through angiogenesis 
or driving chemotactic migration of immune cells [24]. 
In this study, in vitro assays reaffirm that one impact of 
tumor-derived CXCL8 from PTEN-deficient tumor cells 
is to enhance chemotactic migration of macrophages. 
Furthermore, we have shown that radiation-induced 
macrophage infiltration may also be inhibited by blockade 
of CXCL8 signaling. Through immunohistochemical 
analysis of human prostate cancer tissue, we have 
demonstrated that loss of PTEN-expression correlates 
with a greater incidence of macrophage infiltration. 
Previous studies have discussed the potential relevance of 
TAMs in patients treated by RP [25, 26]. Using optimized 
in vitro systems, we have shown that co-culture with 
macrophage representative THP-1 cells increased the 
radio-resistance of CaP cells, suggesting that the higher 
level of macrophage infiltration in PTEN-deficient tumors 
may underpin their adverse prognosis with respect to 
radiotherapy (4).
Founded on the detection of macrophage enrichment 
in PTEN-deficient prostate tumors, we evaluated how 
the cellular compartments, studied in isolation and in 
co-culture responded to clinically-relevant doses of IR. 
Cytokine arrays were conducted to determine how 
Figure 4: Impact of radiation-induced THP-1 derived TNF-α on NFκB pro-survival signaling. (A) Bar graph illustrating 
luciferase reporter assay analysis of NFκB activity in Sh11.02 cells. Different experimental conditions included THP-1 co-culture, exposure 
to 3 Gy IR and treatment with a TNF-α neutralizing antibody (10 ng/ml). (B) Immunoblot showing basal expression of NFκB-regulated 
anti-apoptotic targets in PTEN-modulated DU145 populations. (C) Immunoblot showing the effect of 10 ng/ml recombinant TNF-α 
treatment on expression of NFκB-regulated anti-apoptotic targets in Sh11.02 cells. (D) Immunoblot illustrating expression of NFκB targets 
in Sh11.02 cells 4 h following 3 Gy IR in the presence or absence of THP-1 co-culture and TNF-α neutralizing antibody. Data shown is the 
mean plus or minus standard error of the mean value, calculated from a minimum of three independent experiments. Statistically significant 
differences in luciferase assay results were determined by performing a two-tailed Students t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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exposure to radiation may affect the secretion of these 
factors. Our data confirms that prostate epithelial cells and 
macrophages are both a rich source of constitutive TNF-α 
secretion in vitro. Profiling of micro-dissected tumor 
epithelial tissue also confirms equivalent expression of 
this inflammatory marker in both PTEN-expressing and 
PTEN-deficient contexts. Experimental data indicated 
that exposure to IR further induced TNF-α secretion from 
THP-1 cells but had no effect on further potentiating 
the endogenous levels of secreted TNF-α from 
PTEN-deficient Sh11.02 cells. Extrapolating to the 
treatment of patients, this would suggest that the altered 
constitution of the microenvironment and especially, the 
density of TAM infiltration in PTEN-deficient tumors 
would be an important determinant in dictating the impact 
of radiation in increasing the local concentration of 
bioactive TNF-α present within tumor foci.
TNF-α is known to be an activator of either 
apoptotic or pro-survival signaling [12]. Switching 
between survival- and death-promoting signaling is 
principally dependent on its ability to activate NFκB 
transcription [27, 28]. Consistent with the resistance 
of CaP cells to clinically relevant doses of TNF-α, this 
cytokine was shown to increase NFκB signaling and 
increase expression of c-FLIP, cIAP-1 and Bcl-2, three 
known NFκB-regulated anti-apoptotic targets in prostate 
cancer cells (30, 31). The activation of NFκB was 
further increased following radiation and constitution of 
macrophage-enriched tumor microenvironment, but was 
inhibited by blockade of TNF-α signaling. Expression 
of c-FLIP and cIAP-1 was further increased in irradiated 
CaP cells in the presence of THP-1 cells, suggesting that 
the inhibition of caspase-dependent apoptosis may be one 
principal underlying mechanism of resistance afforded by 
this cytokine. 
The mode-of-action of cIAP-1 is well understood. 
This protein is recruited to death receptors following 
ligand binding and is responsible for resultant NFκB 
activation by promoting the polyubiquitination of RIP-1 
kinase (RIP1) [29]. Inhibition of cIAP-1 is therefore 
viewed as an attractive and potential amenable target 
to direct the downstream fate stemming from cytokine 
Figure 5: Impact of AT-IAP on cIAP-1 expression and DU145 Sh11.02 cell viability. (A) Immunoblot showing cIAP-1 
expression in Sh11.02 cells following treatment with 0.1, 1 or 10 µM AT-IAP. Equal protein loading was confirmed by re-probing for 
GAPDH. (B) Bar graph presenting MTT assay analysis of Sh11.02 cells 72 h following treatment with 10 ng/ml rhTNF-α, 1 µM AT-IAP, or 
a combination of both. (C) Bar graph illustrating flow cytometry data following Annexin V/PI staining of Sh11.02 cells. Different treatment 
conditions were similar to those mentioned above. (D) Bar graph showing caspase 3/7 activity of Sh11.02 cells following treatment with 
rhTNF-α, AT-IAP or both in combination for 24 h. Data shown is the mean plus or minus standard error of the mean value, calculated 
from a minimum of three independent experiments. Statistically significant differences were determined by performing a two-tailed 
Students t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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Figure 6: Assessment of the radiosensitizing potential of AT-IAP in Sh11.02 cells. (A) Immunoblot showing cIAP-1 expression 
in Sh11.02 cells following THP-1 co-culture, 3 Gy IR and treatment with 0.1 µM AT-IAP. Equal protein loading was confirmed by 
re-probing for GAPDH. (B) Bar graph showing caspase 3/7 activity in Sh11.02 cells following THP-1 co-culture, 3 Gy IR and treatment 
with 0.1 µM AT-IAP for 6 h. (C) Clonogenic survival curve showing the radiosensitizing potential of AT-IAP on Sh11.02 cells with THP-1 
co-culture. Data showing addition of a TNF-α neutralizing antibody in this system is also presented. Data shown is the mean plus or minus 
standard error of the mean value, calculated from a minimum of three independent experiments. Statistically significant differences were 
determined by performing a two-tailed Students t-test or two-way ANOVA for clonogenic assays (*p < 0.05; **p < 0.01; ***p < 0.001).
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signaling, switching from primarily a cell survival 
response to a pro-apoptotic cell death phenotype. Several 
Smac-mimetics, have demonstrated efficacy in a range 
of cancer types [30, 31], including prior demonstration 
that they can enhance radiotherapy sensitivity in CaP 
xenograft models [32]. In our hands, treatment with a 
novel IAP antagonist, AT-IAP, ablated the expression 
of cIAP-1 in DU145 Sh11.02 cells, consistent with a 
proteasome-dependent degradation of the protein. When 
combined with exogenous TNF-α, AT-IAP reversed the 
resistance of CaP cells to this cytokine, and significantly 
reduced cell viability by promoting apoptosis in vitro. 
Moreover, AT-IAP retained the capacity to augment 
apoptosis levels in irradiated CaP cells in the co-
culture model, consistent with this agent working in 
synergy with radiation-induced macrophage-derived 
TNF-α. Moreover, in clonogenic survival assays, the 
administration of AT-IAP reversed the resistance afforded 
by macrophages, instead increasing the sensitivity of 
PTEN-deficient Sh11.02 cells to clinically-relevant 
doses of external-beam radiotherapy. 
Macrophage-derived TNF-α signaling has 
previously been implicated in promoting radio-resistance 
in in vivo models of melanoma [7]. We have detected the 
enrichment of macrophages in PTEN-deficient prostate 
tumors, and extrapolating to use of co-culture models, 
we have demonstrated the relevance of macrophages and 
TNF-α signaling in contributing to the radio-resistance of 
CaP cells. Moreover, our experimental data reveals that use 
of an IAP antagonist confers increased radio-sensitivity of 
PTEN-deficient cancer cells, exploiting the inflammatory 
potential of the macrophage-enriched microenvironment.
CONCLUSION
PTEN-deficient tumors exhibit an elevated 
macrophage infiltration underpinning increased 
macrophage-promoted TNF-α signaling that promotes 
survival of CaP cells through up-regulation of 
anti-apoptotic proteins including cIAP-1. Treatment 
with a novel cIAP-1 antagonist, AT-IAP, sensitizes 
malignant prostate cells to radiotherapy, suggesting that 
Smac mimetics may be a relevant therapeutic strategy 
for enhancing the effect of ionizing radiation in patients 
presenting with PTEN-deficient CaP.
MATERIALS AND METHODS
Reagents
Recombinant human TNF-α was purchased from 
Alomone Labs (Jerusalem, Israel) and cells were treated 
at a final concentration of 10 ng/ml. Human TNF-α 
neutralizing antibody was obtained from Cell Signaling 
(Beverly, MA, USA) and cells were treated at a final 
concentration of 10 ng/ml. Recombinant human CXCL8 
was purchased from Peprotech (London, UK) and cells 
were treated at a final concentration of 3 nM. Human 
CXCL8 neutralizing antibody was obtained from R & D 
Systems (Abingdon, UK). AT-IAP was supplied by Astex 
Pharmaceuticals (Cambridge, UK) and reconstituted in 
DMSO before treating at a final concentration of 1 µM 
unless otherwise stated.
Cell line and cell culture
Authenticated DU145 prostate cancer cells were 
obtained from American Type Culture Collection (ATCC); 
PTEN expression was depleted and cells cultured as 
previously described [5]. Human macrophage-like THP-1 
cells were maintained in RPMI medium supplemented 
with 10% FCS and 0.05 mM β-mercaptoethanol. In all 
co-culture experiments, THP-1 cells were seeded at a 
density which represented 20% of the prostate cancer cell 
population. Cells were regularly tested to ensure they were 
free of mycoplasma contamination. 
DNA and RNA extraction from FFPE clinical 
samples
Twenty-eight Gleason 7 grade prostate tumour FFPE 
blocks were obtained from the Northern Ireland Biobank 
(NIB13–0074). Sequential 4 μm sections of each case were 
cut and placed on glass slides (a total of 20 μm). The tumour 
regions were then macro-dissected into sterile 1.5 ml 
Eppendorf tubes. The RNA was extracted using the Qiagen 
RNAeasy kit according to manufacturer’s instructions. 
Genomic DNA was extracted using the Promega Genomic 
DNA extraction kit. All standard procedures were taken 
according to the manufacturer’s protocol. Extracted DNA 
and RNA was quantified and assessed for their quality using 
the Agilent Bioanalyser chips.
Whole genome gene expression (WG-DASL)
Whole genome gene expression analysis was 
performed using the Illumina (San Diego, CA, USA) 
WG-DASL assay according to manufacturer’s protocol. 
Briefly, 100 ng of FFPE RNA was converted to cDNA by 
the WG-DASL assay using biotinylated-tagged random 
nonamer and oligo (dT) primers. The biontinylated 
cDNA was then mounted onto a streptavidin-coated 
support and further extended and ligated by gene-specific 
oligonucleotides (DAP). Subsequently, PCR amplification 
was performed. The resulting PCR products were eluted 
and hybridized to the Illumina Human-Ref v3.0 Beadchip 
and scanned with the Illumina iScan Reader.  The image 
intensity values from the microarray images generated 
were then analysed by the GenomeStudio Gene Expression 
Module (Illumina, San Diego, CA, USA) software. The 
processed methylation values were subsequently used for 
further analysis in this study.
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Whole genome methylation
Whole genome methylation analysis was performed 
using the Illumina Infinium HD (San Diego, CA, USA) 
assay according to manufacturer’s protocol. Briefly, 
1000 ng of genomic DNA extracted from the FFPE 
samples was firstly treated with sodium bisuphite to 
convert unmethylated cytosine to uracil. The bisulphite 
treated DNA was denatured isothermally and amplified 
overnight. After amplification, the post-amplified DNA 
was fragmented using a proprietary enzymatic process 
and precipitated using isopropanol. The precipitated DNA 
was then collected by centrifugation and re-suspended 
in a hybridization buffer. The hybridized product was 
then hybridized onto the Infinium 450K Beadchip. The 
loaded chip underwent further extension and staining 
steps. Subsequently, the Illumina iScan reader was used to 
derive image intensity values off the stained chip from the 
high-resolution scans of the chip. The image 
intensity values was processed and normalized by the 
GenomeStudio Gene Expression Module (Illumina, San 
Diego, CA, USA). The processed methylation values were 
subsequently used for further analysis in this study.
Immunohistochemistry
Tissue microarrays consisting of Gleason 6 (N = 
15) and Gleason 7 (N = 55) prostate tumors were obtained 
from the Northern Ireland Biobank. Consecutive TMA 
paraffin sections of 4 μm thickness were cut and placed 
onto silanated slides for immunohistochemical detection 
of PTEN and CD68 using a Bond-Max autostainer 
(Leica Biosystems, Newcastle, UK). Standard processing 
steps were performed according to manufacturer’s 
instructions. Briefly, heat-induced antigen retrieval with 
epitope retrieval ER1 solution (Leica Biosystems) was 
performed for 20 min prior to incubation with primary 
antibody. Slides were incubated with PTEN (Cascade 
Bioscience, clone 6H2.1, dilution 1:400) or CD68 
(BD Pharmingen, clone KP1, dilution 1:250). After 
incubation, slides were washed with Bond washing 
buffer (Leica Biosystems) and incubated with secondary 
antibody (Bond Polymer Refine kit, Leica Biosystems). 
Subsequently chromogenic detection was achieved 
by incubation with 3, 30-diaminobenzidine (DAB) 
followed by Bond DAB enhancer (Leica Biosystems). 
All slides were counterstained with haematoxylin and 
dehydrated through ascending ethanol to xylene before 
mounting. Expression of PTEN was scored either as 
positive (retention of cytoplasmic staining) or negative 
(lack of staining). Expression of CD68 was scored based 
on their staining pattern (either dense or sparse) of the 
macrophages.
Western blotting analysis
Whole cell lysates were prepared, resolved and 
blotted as previously described [5]. Membranes were 
probed with the following primary antibodies: anti-PTEN 
(Cell Signaling, Beverly, MA, USA); anti-c-FLIP (Enzo Life 
Sciences, Exeter, UK); anti-cIAP-1 (Santa Cruz, Heidelberg, 
Germany); anti-Bcl-2 (Cell Signaling, Beverly, MA, USA); 
anti-TNFR-1 (Santa Cruz, Heidelberg, Germany); and 
anti-Caspase-8 (Millipore, Billerica, MA, USA) at 4°C 
overnight. Membranes were washed three times with 1X 
PBS + 0.05% Tween-20 before being incubated with the 
appropriate horseradish peroxidase (HRP)-tagged secondary 
antibody (GE Healthcare, UK). Immunolabelled proteins 
were detected using the Luminata Crescendo substrate 
(Millipore, Billerica, MA, USA). Membranes were reprobed 
with GAPDH primary antibody (ABD Serotec, UK) to 
ensure equal loading.
Radiation treatments
Cells were exposed to 225 kVp x-rays using the 
self-contained X-RAD 225 irradiation system (Precision 
X-Ray Inc., Connecticut, USA). All experiments were 
performed at a dose rate of 0.52 Gy min−1.
Chemotaxis assay
Analysis of THP-1 chemotaxis was performed using 
the 5 µm pore size CytoSelect™ 96-Well Cell Migration 
Assay kit (Cell Biolabs) according to manufacturer’s 
instructions. For conditioned media experiments, prostate 
cancer cells were treated with a 3 Gy dose of IR and 
incubated at 37oC for 6 h prior to collecting media.
Clonogenic assays
Prostate cancer cells were plated into 6-well plates at 
a final density determined by the dose of IR to be received. 
At the same time, THP-1 cells were added directly to each 
well intended for co-culture at a density that was 20% 
of the total CaP cell number. Cells were left to incubate 
at 37°C overnight before being treated accordingly the 
following morning. For AT-IAP treatments, cells were 
allowed to incubate for 1 h prior to being irradiated. 
Following IR, plates were returned to the incubator for 
10–14 days until colonies in the control plate had reached 
a size of 50 cells or more. THP-1 cells were removed 
by rinsing the wells with 1X PBS prior to fixation and 
staining by 0.4% crystal violet. Surviving fractions (SF) 
were calculated relative to non-irradiated cells and fitted 
using a linear quadratic function (S = exp(-αD -βD2)) 
using least-squares regression (Prism 5.0; GraphPad 
Software, CA). Area under-the-curve (AUC) representing 
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the mean inactivation dose (MID) was obtained and dose 
enhancement factor (DEF) calculated by dividing the MID 
of the control by that of the treated group.
ELISA
Secreted CXCL8 and TNF-α in culture media 
were analyzed using commercially available ELISA kits 
(Pelikine, Beckman Coulter, High Wycombe, UK and 
Biolegend, London, UK respectively) as previously 
described [5].
Luciferase reporter assay
NFκB luciferase assays were performed using the 
NFκB-LUC-PGL4 plasmid (Promega, Southampton, UK) 
as previously described [20].
Detection of apoptosis
Cells were seeded at a density of 1 × 105 into 6-well 
plates and left to adhere overnight. Cells were then treated 
with either rhTNF-α, AT-IAP or both and returned to the 
incubator for 72 h. Whole culture medium was collected 
and pooled with the corresponding trypsinized cells before 
being pelleted via centrifugation at 1000 rpm. Cell pellets 
were resuspended in 100 µl of binding buffer and 5 µl of 
Annexin V antibody (Life Technologies, Paisley, UK) was 
added to each sample alongside 5 µl of propidium iodide 
(PI) stain (50 µg/ml). Samples were incubated in darkness 
for 15 min before adding 320 µl of binding buffer and 
analyzing on the EPICS XL flow cytometer (Beckman 
Coulter, Buckinghamshire, UK). Caspase 3/7 activity 
assays were performed according to manufacturer’s 
instructions (Promega, UK).
MTT assay
Cells were treated with rhTNF-α, AT-IAP or both 
for 72 h and cell viability was then assessed as previously 
described [21].
Statistical analysis
Statistically significant differences between means 
were determined using a two-tailed Students t-test. 
Statistical significance between different treatment groups 
following clonogenic survival assay were determined by 
performing a two-way ANOVA. All significant statistical 
differences were defined as P < 0.05 (*), P < 0.01 (**) and 
P < 0.001 (***).
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